Amendment No. 4 to Schedule 13D for Climb Bio, Inc.

This Amendment No. 4 to Schedule 13D is filed by AI ETI LLC, Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik (collectively, the "Reporting Persons") regarding their holdings in Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.). The amendment reflects material changes since the last filing, including the change of the issuer's name from "Eliem Therapeutics, Inc." to "Climb Bio, Inc." effective October 2, 2024. The amendment also details recent transactions involving the sale of common stock by AI ETI LLC, including multiple open market transactions and a block trade. The Reporting Persons collectively own 3,835,117 shares of common stock, representing approximately 5.66% of the outstanding shares. The filing includes a joint filing agreement dated October 7, 2025.